European Investor
02 Jun 2026, 20:27
Legend Biotech Soars 39% as Early In Vivo CAR-T Data Impress Investors
Shares of Legend Biotech (NASDAQ: LEGN) surged 39% after the company reported promising early clinical data for LB2501, its investigational in vivo CAR-T therapy for relapsed or refractory non-Hodgkin lymphoma (NHL).
The Phase 1 study showed particularly strong efficacy in the higher-dose cohort. Among six patients treated at dose level 2, the objective response rate was 100%, while 83.3% achieved a complete response. Importantly, all responses remained ongoing at the time of the data cutoff.
Investors were also encouraged by the therapy's safety profile. The company reported no dose-limiting toxicities, no serious adverse events, no deaths, and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS). All observed cytokine release syndrome (CRS) events were mild, with no cases above Grade 2.
LB2501 is designed to generate CAR-T cells directly inside the patient following a single infusion, potentially eliminating the need for complex cell manufacturing and lymphodepleting chemotherapy. The treatment targets both CD19 and CD20 and could represent a significant advance in making CAR-T therapies more accessible and scalable.
The data will be presented in a late-breaking oral session at the European Hematology Association (EHA) Congress later this month, further highlighting the significance of the results.
The sharp rally reflects investor enthusiasm for what could become a first-in-class in vivo CAR-T platform, with the early data suggesting the potential to combine strong efficacy, favorable safety, and a much simpler treatment process than traditional CAR-T therapies.
Shares of Legend Biotech (NASDAQ: LEGN) surged 39% after the company reported promising early clinical data for LB2501, its investigational in vivo CAR-T therapy for relapsed or refractory non-Hodgkin lymphoma (NHL).
The Phase 1 study showed particularly strong efficacy in the higher-dose cohort. Among six patients treated at dose level 2, the objective response rate was 100%, while 83.3% achieved a complete response. Importantly, all responses remained ongoing at the time of the data cutoff.
Investors were also encouraged by the therapy's safety profile. The company reported no dose-limiting toxicities, no serious adverse events, no deaths, and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS). All observed cytokine release syndrome (CRS) events were mild, with no cases above Grade 2.
LB2501 is designed to generate CAR-T cells directly inside the patient following a single infusion, potentially eliminating the need for complex cell manufacturing and lymphodepleting chemotherapy. The treatment targets both CD19 and CD20 and could represent a significant advance in making CAR-T therapies more accessible and scalable.
The data will be presented in a late-breaking oral session at the European Hematology Association (EHA) Congress later this month, further highlighting the significance of the results.
The sharp rally reflects investor enthusiasm for what could become a first-in-class in vivo CAR-T platform, with the early data suggesting the potential to combine strong efficacy, favorable safety, and a much simpler treatment process than traditional CAR-T therapies.